Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2002

01-05-2002 | Letter to the Editor

Imatinib Mesylate (Gleevec) in the Treatment of 2 Patients with Philadelphia-Positive ALL Relapsing after Allogeneic Stem Cell Transplantation

Authors: Keiji Sugimoto, Michiaki Mikoshiba, Kazuteru Ohashi, Hideki Akiyama, Hisashi Sakamaki

Published in: International Journal of Hematology | Issue 4/2002

Login to get access
Metadata
Title
Imatinib Mesylate (Gleevec) in the Treatment of 2 Patients with Philadelphia-Positive ALL Relapsing after Allogeneic Stem Cell Transplantation
Authors
Keiji Sugimoto
Michiaki Mikoshiba
Kazuteru Ohashi
Hideki Akiyama
Hisashi Sakamaki
Publication date
01-05-2002
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2002
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02982139

Other articles of this Issue 4/2002

International Journal of Hematology 4/2002 Go to the issue

OriginalPaper

Mast Cells Derived from Embryonic Stem Cells: A Model System for Studying the Effects of Genetic Manipulations on Mast Cell Development, Phenotype, and Function In Vitro and In Vivo

OriginalPaper

Signal Transduction—Associated and Cell Activation—Linked Antigens Expressed in Human Mast Cells

Review Article

cDNA Microarray Analysis of Chronic Myeloid Leukemia

Review Article

Signal Transduction of Chemokine Platelet Factor 4 in Human Erythroleukemia Cells

Case Report

Epstein-Barr Virus-Associated B-Cell Type Non-Hodgkin’s Lymphoma with Concurrent p53 Protein Expression in a Rheumatoid Arthritis Patient Treated with Methotrexate

Letter to the Editor

Acute Lymphoblastic Leukemia with t(1;9;22)(q32;q34;Q11)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits